SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: sam who wrote (5870)1/11/1999 11:07:00 AM
From: Joe E.  Read Replies (1) of 6136
 
Title of article:
"Zarix, Limited Acquires Rights to THYMITAQ(TM) From Agouron Pharmaceuticals, Inc."

IMO this is a nice though probably small development for Agouron. Thymitaq has definite possibilities as a cancer drug, but appears to have been rather toxic in Agouron's tests, as are many cancer drugs.

My recollection is that the decision to discontinue testing of Thymitaq by AGPH was somewhat unpopular, as the drug, in addition to getting responses when used alone, was reported to work well with radiation therapy, but this combination was not trial-tested by AGPH before the decision was made to stop working on Thymitaq.

I am happy to see AGPH derive at least some value from it work.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News